haloperidol has been researched along with Nausea in 55 studies
Haloperidol: A phenyl-piperidinyl-butyrophenone that is used primarily to treat SCHIZOPHRENIA and other PSYCHOSES. It is also used in schizoaffective disorder, DELUSIONAL DISORDERS, ballism, and TOURETTE SYNDROME (a drug of choice) and occasionally as adjunctive therapy in INTELLECTUAL DISABILITY and the chorea of HUNTINGTON DISEASE. It is a potent antiemetic and is used in the treatment of intractable HICCUPS. (From AMA Drug Evaluations Annual, 1994, p279)
haloperidol : A compound composed of a central piperidine structure with hydroxy and p-chlorophenyl substituents at position 4 and an N-linked p-fluorobutyrophenone moiety.
Nausea: An unpleasant sensation in the stomach usually accompanied by the urge to vomit. Common causes are early pregnancy, sea and motion sickness, emotional stress, intense pain, food poisoning, and various enteroviruses.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The purpose of the study was to compare efficacy and toxicity of olanzapine (OLN; a higher-cost drug) and haloperidol (HAL; a lower-cost drug) in the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients who receive highly emetogenic chemotherapy (HEC)." | 9.30 | Randomized Phase II Trial to Compare the Efficacy of Haloperidol and Olanzapine in the Control of Chemotherapy-Induced Nausea and Vomiting in Nepal. ( Acharya, B; Dulal, S; Neupane, P; Paudel, BD; Poudyal, BS; Shah, A; Shilpakar, R; Wood, LA, 2019) |
| "Haloperidol as an adjunctive therapy is superior to placebo for acute gastroparesis symptoms." | 9.24 | Randomized Controlled Double-blind Trial Comparing Haloperidol Combined With Conventional Therapy to Conventional Therapy Alone in Patients With Symptomatic Gastroparesis. ( Cardenas-Turanzas, M; Chambers, KA; Chathampally, Y; Paniagua, L; Patel, S; Roldan, CJ, 2017) |
| "Haloperidol is used commonly for the control of nausea and vomiting (N/V) in palliative care patients, but there is very little evidence to support its use." | 9.14 | The efficacy of haloperidol in the management of nausea and vomiting in patients with cancer. ( Douglas, C; Gilshenan, K; Hardy, JR; O'Shea, A; Welch, L; White, C, 2010) |
| " This study compared ziprasidone with the conventional antipsychotic haloperidol in outpatients with stable schizophrenia." | 9.10 | A 28-week comparison of ziprasidone and haloperidol in outpatients with stable schizophrenia. ( Bäuml, J; Hirsch, SR; Kissling, W; O'Connor, R; Power, A, 2002) |
| "Tropisetron is a novel antiserotoninergic drug with potent and specific activity against cancer chemotherapy-induced emesis." | 9.07 | Tropisetron plus haloperidol to ameliorate nausea and vomiting associated with high-dose alkylating agent cancer chemotherapy. ( Bonadonna, G; Bregni, M; Di Nicola, M; Gianni, AM; Siena, S, 1991) |
| "The antiemetic effectiveness of haloperidol plus dexamethasone was compared with that of prochlorperazine plus dexamethasone in a prospective study of patients receiving chemotherapy for breast cancer." | 9.06 | A randomized comparison of haloperidol plus dexamethasone versus prochlorperazine plus dexamethasone in preventing nausea and vomiting in patients receiving chemotherapy for breast cancer. ( Carpenter, JT; Conolley, C; Lee, J; Silvey, L; Wheeler, RH, 1988) |
| "Sixty-two postoperative patients were admitted to a double-blind study to compare the therapeutic effectiveness of a single intramuscular injection of 1 mg of haloperidol with that of a placebo for the relief of vomiting and nausea following surgical procedures." | 9.04 | The use of haloperidol for treatment of postoperative nausea and vomiting--a double-blind placebo-controlled trial. ( Barton, MD; Cohen, PJ; Libonati, M, 1975) |
| "0 mg) of haloperidol with that of placebo for the relief of vomiting and nausea due to gastrointestinal disorders." | 9.04 | Haloperidol parenterally for treatment of vomiting and nausea from gastrointestinal disorders in a group of geriatric patients: double-blind, placebo-controlled study. ( Nagel, JD; Robbins, EL, 1975) |
| "To evaluate the efficacy and adverse events associated with the use of haloperidol for the treatment of nausea and vomiting in palliative care patients." | 8.91 | Haloperidol for the treatment of nausea and vomiting in palliative care patients. ( Dorman, S; Murray-Brown, F, 2015) |
| "The primary objective of the review was to evaluate the efficacy and adverse events associated with the use of haloperidol for the treatment of nausea and vomiting in palliative care patients." | 8.85 | Haloperidol for the treatment of nausea and vomiting in palliative care patients. ( Dorman, S; Perkins, P, 2009) |
| "Haloperidol (HL) has successfully been used for nausea and abdominal pain in emergency departments (EDs)." | 8.02 | Haloperidol Use in the Emergency Department for Gastrointestinal Symptoms: Nausea, Vomiting, and Abdominal Pain. ( Jehangir, A; Malik, Z; Parkman, HP; Repanshek, ZD; Reznick-Lipina, K; Shahsavari, D; Weiner, M, 2021) |
| " From October 1995 to January 1997, prevention of emesis with granisetron 3 mg/12 h i." | 7.70 | The antiemetic efficacy of granisetron plus dexamethasone, haloperidol and loracepam in breast cancer patients treated with high-dose chemotherapy with peripheral blood stem-cell support. ( Aznar, E; Climent, MA; Guillem, V; Olmos, T; Palau, J; Ruiz, A; Soriano, V, 1998) |
| "Haloperidol (HP) has been shown to have analgesic & antiemetic properties." | 5.46 | Haloperidol undermining gastroparesis symptoms (HUGS) in the emergency department. ( Croft, B; Darracq, MA; Ramirez, R; Stalcup, P, 2017) |
| "The purpose of the study was to compare efficacy and toxicity of olanzapine (OLN; a higher-cost drug) and haloperidol (HAL; a lower-cost drug) in the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients who receive highly emetogenic chemotherapy (HEC)." | 5.30 | Randomized Phase II Trial to Compare the Efficacy of Haloperidol and Olanzapine in the Control of Chemotherapy-Induced Nausea and Vomiting in Nepal. ( Acharya, B; Dulal, S; Neupane, P; Paudel, BD; Poudyal, BS; Shah, A; Shilpakar, R; Wood, LA, 2019) |
| "Haloperidol as an adjunctive therapy is superior to placebo for acute gastroparesis symptoms." | 5.24 | Randomized Controlled Double-blind Trial Comparing Haloperidol Combined With Conventional Therapy to Conventional Therapy Alone in Patients With Symptomatic Gastroparesis. ( Cardenas-Turanzas, M; Chambers, KA; Chathampally, Y; Paniagua, L; Patel, S; Roldan, CJ, 2017) |
| "The topical gel known as "ABH gel," comprising lorazepam (Ativan(®)), diphenhydramine (Benadryl(®)), and haloperidol (Haldol(®)), is frequently used to treat nausea because of its perceived efficacy, relatively low cost, and ease of use in the home setting." | 5.19 | A randomized trial of the effectiveness of topical "ABH Gel" (Ativan(®), Benadryl(®), Haldol(®)) vs. placebo in cancer patients with nausea. ( Coyne, PJ; Dodson, PW; Fletcher, DS; Parker, GG; Smith, TJ; Wan, W, 2014) |
| "Haloperidol is used commonly for the control of nausea and vomiting (N/V) in palliative care patients, but there is very little evidence to support its use." | 5.14 | The efficacy of haloperidol in the management of nausea and vomiting in patients with cancer. ( Douglas, C; Gilshenan, K; Hardy, JR; O'Shea, A; Welch, L; White, C, 2010) |
| " This study compared ziprasidone with the conventional antipsychotic haloperidol in outpatients with stable schizophrenia." | 5.10 | A 28-week comparison of ziprasidone and haloperidol in outpatients with stable schizophrenia. ( Bäuml, J; Hirsch, SR; Kissling, W; O'Connor, R; Power, A, 2002) |
| "Tropisetron is a novel antiserotoninergic drug with potent and specific activity against cancer chemotherapy-induced emesis." | 5.07 | Tropisetron plus haloperidol to ameliorate nausea and vomiting associated with high-dose alkylating agent cancer chemotherapy. ( Bonadonna, G; Bregni, M; Di Nicola, M; Gianni, AM; Siena, S, 1991) |
| "The antiemetic effectiveness of haloperidol plus dexamethasone was compared with that of prochlorperazine plus dexamethasone in a prospective study of patients receiving chemotherapy for breast cancer." | 5.06 | A randomized comparison of haloperidol plus dexamethasone versus prochlorperazine plus dexamethasone in preventing nausea and vomiting in patients receiving chemotherapy for breast cancer. ( Carpenter, JT; Conolley, C; Lee, J; Silvey, L; Wheeler, RH, 1988) |
| "0 mg) of haloperidol with that of placebo for the relief of vomiting and nausea due to gastrointestinal disorders." | 5.04 | Haloperidol parenterally for treatment of vomiting and nausea from gastrointestinal disorders in a group of geriatric patients: double-blind, placebo-controlled study. ( Nagel, JD; Robbins, EL, 1975) |
| "Sixty-two postoperative patients were admitted to a double-blind study to compare the therapeutic effectiveness of a single intramuscular injection of 1 mg of haloperidol with that of a placebo for the relief of vomiting and nausea following surgical procedures." | 5.04 | The use of haloperidol for treatment of postoperative nausea and vomiting--a double-blind placebo-controlled trial. ( Barton, MD; Cohen, PJ; Libonati, M, 1975) |
| "To evaluate the efficacy and adverse events associated with the use of haloperidol for the treatment of nausea and vomiting in palliative care patients." | 4.91 | Haloperidol for the treatment of nausea and vomiting in palliative care patients. ( Dorman, S; Murray-Brown, F, 2015) |
| " In postoperative nausea and vomiting (PONV), two randomized controlled trials found treatment with haloperidol comparable to ondansetron." | 4.89 | Using haloperidol as an antiemetic in palliative care: informing practice through evidence from cancer treatment and postoperative contexts. ( Bennett, MI; Blenkinsopp, A; McLean, SL, 2013) |
| "The primary objective of the review was to evaluate the efficacy and adverse events associated with the use of haloperidol for the treatment of nausea and vomiting in palliative care patients." | 4.85 | Haloperidol for the treatment of nausea and vomiting in palliative care patients. ( Dorman, S; Perkins, P, 2009) |
| "Haloperidol (HL) has successfully been used for nausea and abdominal pain in emergency departments (EDs)." | 4.02 | Haloperidol Use in the Emergency Department for Gastrointestinal Symptoms: Nausea, Vomiting, and Abdominal Pain. ( Jehangir, A; Malik, Z; Parkman, HP; Repanshek, ZD; Reznick-Lipina, K; Shahsavari, D; Weiner, M, 2021) |
| "This randomized controlled trial compared haloperidol along with conventional therapy to placebo along with conventional therapy for gastroparesis in the emergency department." | 3.88 | Hot Off the Press: SGEM#196: Gastroparesis-I Feel Like Throwing Up. ( Heitz, C; Milne, WK; Morgenstern, J, 2018) |
| "For nausea, a commonly encountered symptom in palliative care, clinicians' favored metoclopramide and haloperidol; however, after these choices, there was large variation in antiemetic selection." | 3.80 | Prescribing for nausea in palliative care: a cross-sectional national survey of Australian palliative medicine doctors. ( Agar, M; Currow, DC; To, TH; Yates, P, 2014) |
| " From October 1995 to January 1997, prevention of emesis with granisetron 3 mg/12 h i." | 3.70 | The antiemetic efficacy of granisetron plus dexamethasone, haloperidol and loracepam in breast cancer patients treated with high-dose chemotherapy with peripheral blood stem-cell support. ( Aznar, E; Climent, MA; Guillem, V; Olmos, T; Palau, J; Ruiz, A; Soriano, V, 1998) |
| "5 mg intravenous haloperidol in an effort to improve patient tolerance of cytotoxic chemotherapy and decrease nausea and vomiting." | 3.66 | Lorazepam as an adjunct to antiemetic therapy with haloperidol in patients receiving cytotoxic chemotherapy. ( Coates, A; Fox, RM; Friedlander, ML; Hedley, D; Kearsley, JH; Raghavan, D; Sims, K; Tattersall, MH, 1983) |
| " Ironically, chronic use of cannabis can result in paradoxical effects, including a condition known as cannabinoid hyperemesis syndrome." | 2.61 | Cannabinoid hyperemesis syndrome: An unrecognized cause of nausea and vomiting. ( Forest, CP; Smith, TN; Walsh, A, 2019) |
| "Haloperidol is a butyrophenone neuroleptic agent characterized as a high-affinity dopamine antagonist, originally used for the treatment of schizophrenia." | 2.48 | Role of haloperidol in palliative medicine: an update. ( Prommer, E, 2012) |
| "Haloperidol (HP) has been shown to have analgesic & antiemetic properties." | 1.46 | Haloperidol undermining gastroparesis symptoms (HUGS) in the emergency department. ( Croft, B; Darracq, MA; Ramirez, R; Stalcup, P, 2017) |
| "Treatment with haloperidol (0." | 1.28 | Drug-induced purposeless chewing: animal model of dyskinesia or nausea? ( Iversen, SD; Rupniak, NM; Tye, SJ, 1990) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 17 (30.91) | 18.7374 |
| 1990's | 6 (10.91) | 18.2507 |
| 2000's | 10 (18.18) | 29.6817 |
| 2010's | 18 (32.73) | 24.3611 |
| 2020's | 4 (7.27) | 2.80 |
| Authors | Studies |
|---|---|
| Brown, JM | 1 |
| Wilsey, MJ | 1 |
| Dhana, L | 1 |
| Lonsdale, H | 1 |
| Trajkovski, A | 1 |
| Lang, E | 1 |
| Shahsavari, D | 1 |
| Reznick-Lipina, K | 1 |
| Malik, Z | 1 |
| Weiner, M | 1 |
| Jehangir, A | 1 |
| Repanshek, ZD | 1 |
| Parkman, HP | 1 |
| Rosenthal, J | 1 |
| Howell, M | 1 |
| Earl, V | 1 |
| Malik, M | 1 |
| Ramirez, R | 1 |
| Stalcup, P | 1 |
| Croft, B | 1 |
| Darracq, MA | 1 |
| Roldan, CJ | 1 |
| Chambers, KA | 1 |
| Paniagua, L | 1 |
| Patel, S | 1 |
| Cardenas-Turanzas, M | 1 |
| Chathampally, Y | 1 |
| Heitz, C | 1 |
| Morgenstern, J | 1 |
| Milne, WK | 1 |
| Smith, TN | 1 |
| Walsh, A | 1 |
| Forest, CP | 1 |
| Dulal, S | 1 |
| Paudel, BD | 1 |
| Neupane, P | 1 |
| Shah, A | 1 |
| Acharya, B | 1 |
| Poudyal, BS | 1 |
| Shilpakar, R | 1 |
| Wood, LA | 1 |
| Matsuoka, H | 1 |
| Agar, M | 2 |
| Vandersman, Z | 1 |
| Good, P | 1 |
| Fazekas, B | 1 |
| Brown, L | 1 |
| Hardy, J | 1 |
| Weil, J | 1 |
| Currow, DC | 2 |
| Hickey, JL | 1 |
| Witsil, JC | 1 |
| Mycyk, MB | 1 |
| McLean, SL | 1 |
| Blenkinsopp, A | 1 |
| Bennett, MI | 1 |
| Kishi, T | 1 |
| Mukai, T | 1 |
| Matsuda, Y | 1 |
| Iwata, N | 1 |
| Silvestris, N | 1 |
| Brunetti, AE | 1 |
| Russano, M | 1 |
| Nardulli, P | 1 |
| Fletcher, DS | 1 |
| Coyne, PJ | 1 |
| Dodson, PW | 1 |
| Parker, GG | 1 |
| Wan, W | 1 |
| Smith, TJ | 1 |
| To, TH | 1 |
| Yates, P | 1 |
| Murray-Brown, F | 1 |
| Dorman, S | 2 |
| Górska, A | 1 |
| Marszałł, M | 1 |
| Sloderbach, A | 1 |
| Inayat, F | 1 |
| Virk, HU | 1 |
| Ullah, W | 1 |
| Hussain, Q | 1 |
| Perkins, P | 1 |
| Hardy, JR | 1 |
| O'Shea, A | 1 |
| White, C | 2 |
| Gilshenan, K | 1 |
| Welch, L | 1 |
| Douglas, C | 1 |
| Prommer, E | 1 |
| Citrome, L | 1 |
| DYRBERG, V | 1 |
| Vella-Brincat, J | 1 |
| Macleod, AD | 1 |
| Buss, MK | 1 |
| Arnold, RM | 1 |
| Krakauer, EL | 1 |
| Zhu, AX | 1 |
| Bounds, BC | 1 |
| Sahani, D | 1 |
| McDonald, KR | 1 |
| Brachtel, EF | 1 |
| Weschules, DJ | 1 |
| McPherson, A | 1 |
| McCann, MA | 1 |
| Sadler, A | 1 |
| Fyvie, J | 1 |
| Siden, HB | 1 |
| Bleicher, J | 1 |
| Bhaskara, A | 1 |
| Huyck, T | 1 |
| Constantino, S | 1 |
| Bardia, A | 1 |
| Loprinzi, CL | 1 |
| Silberstein, PT | 1 |
| Friedlander, ML | 1 |
| Kearsley, JH | 1 |
| Sims, K | 1 |
| Coates, A | 1 |
| Hedley, D | 1 |
| Raghavan, D | 1 |
| Fox, RM | 1 |
| Tattersall, MH | 1 |
| Uvnäs-Wallensten, K | 1 |
| Goiny, M | 1 |
| Judkins, KC | 1 |
| Harmer, M | 1 |
| Cole, RM | 1 |
| Robinson, F | 1 |
| Harvey, L | 1 |
| Trethowan, K | 1 |
| Murdoch, V | 1 |
| Climent, MA | 1 |
| Palau, J | 1 |
| Ruiz, A | 1 |
| Soriano, V | 1 |
| Aznar, E | 1 |
| Olmos, T | 1 |
| Guillem, V | 1 |
| Mickle, J | 1 |
| Critchley, P | 1 |
| Plach, N | 1 |
| Grantham, M | 1 |
| Marshall, D | 1 |
| Taniguchi, A | 1 |
| Latimer, E | 1 |
| Jadad, AR | 1 |
| Hirsch, SR | 1 |
| Kissling, W | 1 |
| Bäuml, J | 1 |
| Power, A | 1 |
| O'Connor, R | 1 |
| Angrist, B | 1 |
| Ain, M | 1 |
| Rotrosen, J | 1 |
| Gershon, S | 1 |
| Halpern, FS | 1 |
| Sachar, EJ | 1 |
| Robbins, EL | 1 |
| Nagel, JD | 1 |
| Barton, MD | 1 |
| Libonati, M | 1 |
| Cohen, PJ | 1 |
| Bregni, M | 1 |
| Siena, S | 1 |
| Di Nicola, M | 1 |
| Bonadonna, G | 1 |
| Gianni, AM | 1 |
| Francom, M | 1 |
| Rupniak, NM | 1 |
| Tye, SJ | 1 |
| Iversen, SD | 1 |
| Backonja, M | 1 |
| Beinlich, B | 1 |
| Dulli, D | 1 |
| Schutta, HS | 1 |
| Murakami, M | 1 |
| Ota, K | 1 |
| Silvey, L | 1 |
| Carpenter, JT | 1 |
| Wheeler, RH | 1 |
| Lee, J | 1 |
| Conolley, C | 1 |
| Venning, M | 1 |
| Rogers, J | 1 |
| Plotkin, DA | 1 |
| Plotkin, D | 1 |
| Okun, R | 1 |
| Christman, RS | 1 |
| Weinstein, RA | 1 |
| Larose, JB | 1 |
| Chibanguza, G | 1 |
| Cole, DR | 1 |
| Duffy, DF | 1 |
| Wolff, JD | 1 |
| Lionarons, HB | 1 |
| Mesdag, MJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Haloperidol vs Conventional Therapy for Gastroparesis[NCT02057549] | Phase 4 | 36 participants (Actual) | Interventional | 2012-11-30 | Terminated (stopped due to PI left institution) | ||
| Droperidol on Prevention of Emesis From Cannabinoid Hyperemesis Syndrome[NCT05244460] | Phase 3 | 45 participants (Anticipated) | Interventional | 2021-12-02 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"The time frame starts from the moment of receiving the study drug to the time when the decision for final disposition is made. Usually after symptoms are controlled, patients are given a PO challenge (food or drink) in order to establish if they are OK to go home. If symptoms return, additional medications are given, the treatment is consider failed and they are admitted to the Hospital.~Patients will not be followed up if admitted to any service. The study ends when final disposition is made.~Patients follow up after final disposition is not part of the study and will not be done." (NCT02057549)
Timeframe: at the time the decision for final disposition is made (about 8 hours)
| Intervention | hours (Median) |
|---|---|
| Haloperidol Plus Conventional Therapy | 4.8 |
| Conventional Therapy | 9 |
(NCT02057549)
Timeframe: 1 hour after study medication given
| Intervention | Participants (Count of Participants) |
|---|---|
| Haloperidol Plus Conventional Therapy | 11 |
| Conventional Therapy | 13 |
The Visual Analogue Scale (VAS) ranges from 1-5, with 1 being minimal nausea and 5 being severe nausea. (NCT02057549)
Timeframe: 1 hour after study medication given
| Intervention | units on a scale (Mean) |
|---|---|
| Haloperidol Plus Conventional Therapy | 1.83 |
| Conventional Therapy | 3.39 |
The Visual Analogue Scale (VAS) ranges from 1-5, with 1 being minimal nausea and 5 being severe nausea. (NCT02057549)
Timeframe: before study medication given
| Intervention | units on a scale (Mean) |
|---|---|
| Haloperidol Plus Conventional Therapy | 4.53 |
| Conventional Therapy | 4.11 |
(NCT02057549)
Timeframe: 2 hours after study medication given
| Intervention | Participants (Count of Participants) |
|---|---|
| Haloperidol Plus Conventional Therapy | 4 |
| Conventional Therapy | 13 |
(NCT02057549)
Timeframe: 1 hour after study medication given
| Intervention | Participants (Count of Participants) |
|---|---|
| Haloperidol Plus Conventional Therapy | 11 |
| Conventional Therapy | 5 |
The Visual Analogue Scale (VAS) ranges from 0-10, with 0 being the absence of pain and 10 the worst imaginable pain. (NCT02057549)
Timeframe: 1 hour after study medication given
| Intervention | units on a scale (Mean) |
|---|---|
| Haloperidol Plus Conventional Therapy | 3.13 |
| Conventional Therapy | 7.17 |
The Visual Analogue Scale (VAS) ranges from 0-10, with 0 being the absence of pain and 10 the worst imaginable pain. (NCT02057549)
Timeframe: before study medication given
| Intervention | units on a scale (Mean) |
|---|---|
| Haloperidol Plus Conventional Therapy | 8.50 |
| Conventional Therapy | 8.28 |
10 reviews available for haloperidol and Nausea
| Article | Year |
|---|---|
Cannabinoid hyperemesis syndrome: An unrecognized cause of nausea and vomiting.
Topics: Acute Disease; Antiemetics; Cannabinoids; Haloperidol; Humans; Lorazepam; Nausea; Syndrome; Vomiting | 2019 |
Using haloperidol as an antiemetic in palliative care: informing practice through evidence from cancer treatment and postoperative contexts.
Topics: Antiemetics; Antineoplastic Agents; Haloperidol; Humans; Nausea; Ondansetron; Palliative Care; Posto | 2013 |
Selective serotonin 3 receptor antagonist treatment for schizophrenia: meta-analysis and systematic review.
Topics: Antipsychotic Agents; Constipation; Double-Blind Method; Drug Therapy, Combination; Granisetron; Hal | 2014 |
Haloperidol for the treatment of nausea and vomiting in palliative care patients.
Topics: Antiemetics; Diphenhydramine; Gels; Haloperidol; Humans; Lorazepam; Nausea; Palliative Care; Randomi | 2015 |
[The neurotoxicity of pyridinium metabolites of haloperidol].
Topics: Antipsychotic Agents; Biotransformation; Brain; Delirium; Haloperidol; Humans; Nausea; Neurodegenera | 2015 |
Haloperidol for the treatment of nausea and vomiting in palliative care patients.
Topics: Antiemetics; Haloperidol; Humans; Nausea; Palliative Care; Vomiting | 2009 |
Role of haloperidol in palliative medicine: an update.
Topics: Delirium; Dopamine Antagonists; Haloperidol; Humans; Nausea; Palliative Care; Vomiting | 2012 |
Haloperidol in palliative care.
Topics: Antipsychotic Agents; Conscious Sedation; Delirium; Haloperidol; Humans; Long QT Syndrome; Nausea; V | 2004 |
Efficacy of haloperidol in the treatment of nausea and vomiting in the palliative patient: a systematic review.
Topics: Antiemetics; Haloperidol; Humans; Nausea; Neoplasms; Palliative Care; Vomiting | 2001 |
[Recent advances in the management of chemotherapy-induced emesis].
Topics: Antiemetics; Antineoplastic Agents; Cisplatin; Dexamethasone; Domperidone; Dronabinol; Drug Therapy, | 1986 |
14 trials available for haloperidol and Nausea
| Article | Year |
|---|---|
Randomized Controlled Double-blind Trial Comparing Haloperidol Combined With Conventional Therapy to Conventional Therapy Alone in Patients With Symptomatic Gastroparesis.
Topics: Abdominal Pain; Adult; Analgesics; Antiemetics; Double-Blind Method; Drug Therapy, Combination; Fema | 2017 |
Randomized Phase II Trial to Compare the Efficacy of Haloperidol and Olanzapine in the Control of Chemotherapy-Induced Nausea and Vomiting in Nepal.
Topics: Administration, Intravenous; Administration, Oral; Adult; Antiemetics; Antineoplastic Combined Chemo | 2019 |
Optimal control of nausea and vomiting with a three-drug antiemetic regimen with aprepitant in metastatic pancreatic cancer patients treated with first-line modified FOLFIRINOX.
Topics: Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Benztropine; Camptoth | 2013 |
A randomized trial of the effectiveness of topical "ABH Gel" (Ativan(®), Benadryl(®), Haldol(®)) vs. placebo in cancer patients with nausea.
Topics: Administration, Topical; Adolescent; Adult; Aged; Antiemetics; Cross-Over Studies; Diphenhydramine; | 2014 |
The efficacy of haloperidol in the management of nausea and vomiting in patients with cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents; Female; Ha | 2010 |
Lurasidone for the acute treatment of adults with schizophrenia: what is the number needed to treat, number needed to harm, and likelihood to be helped or harmed?
Topics: Adult; Akathisia, Drug-Induced; Antipsychotic Agents; Benzodiazepines; Blood Glucose; Cholesterol; D | 2012 |
Haloperidol as an adjunct analgesic in the management of postoperative pain.
Topics: Adolescent; Adult; Aged; Drug Administration Schedule; Drug Synergism; Female; Haloperidol; Humans; | 1982 |
A 28-week comparison of ziprasidone and haloperidol in outpatients with stable schizophrenia.
Topics: Adolescent; Adult; Antipsychotic Agents; Female; Haloperidol; Humans; Male; Middle Aged; Nausea; Pip | 2002 |
Haloperidol parenterally for treatment of vomiting and nausea from gastrointestinal disorders in a group of geriatric patients: double-blind, placebo-controlled study.
Topics: Age Factors; Aged; Antiemetics; Clinical Trials as Topic; Drug Evaluation; Female; Gastrointestinal | 1975 |
The use of haloperidol for treatment of postoperative nausea and vomiting--a double-blind placebo-controlled trial.
Topics: Abdomen; Adolescent; Adult; Aged; Anesthesia, Inhalation; Anesthetics; Clinical Trials as Topic; Col | 1975 |
Tropisetron plus haloperidol to ameliorate nausea and vomiting associated with high-dose alkylating agent cancer chemotherapy.
Topics: Adult; Antiemetics; Antineoplastic Agents; Drug Therapy, Combination; Haloperidol; Humans; Indoles; | 1991 |
A randomized comparison of haloperidol plus dexamethasone versus prochlorperazine plus dexamethasone in preventing nausea and vomiting in patients receiving chemotherapy for breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Cyclopho | 1988 |
Low-dose haloperidol as antiemetic treatment in gastrointestinal disorders: a double-blind study.
Topics: Antiemetics; Clinical Trials as Topic; Dose-Response Relationship, Drug; Female; Gastrointestinal Di | 1974 |
Haloperidol for radiation sickness: Control of associated nausea, vomiting, and anorexia.
Topics: Adult; Aged; Clinical Trials as Topic; Feeding and Eating Disorders; Female; Haloperidol; Humans; Ma | 1974 |
31 other studies available for haloperidol and Nausea
| Article | Year |
|---|---|
Acute Treatment of Adolescent Cannabinoid Hyperemesis Syndrome With Haloperidol, Lorazepam, and/or Capsaicin: A Single Institution Case Series.
Topics: Adolescent; Adult; Cannabinoids; Capsaicin; Child; Haloperidol; Humans; Lorazepam; Nausea; Syndrome; | 2023 |
Haloperidol as an anti-emetic for Cannabis Hyperemesis Syndrome in the ED.
Topics: Antiemetics; Cannabis; Haloperidol; Humans; Nausea; Vomiting | 2021 |
Haloperidol Use in the Emergency Department for Gastrointestinal Symptoms: Nausea, Vomiting, and Abdominal Pain.
Topics: Abdominal Pain; Adult; Antiemetics; Diabetes Mellitus; Emergency Service, Hospital; Female; Florida; | 2021 |
Cannabinoid Hyperemesis Syndrome Secondary to Delta-8 THC Use.
Topics: Administration, Cutaneous; Adult; Antiemetics; Cannabinoid Receptor Agonists; Capsaicin; Dopamine An | 2021 |
Haloperidol undermining gastroparesis symptoms (HUGS) in the emergency department.
Topics: Abdominal Pain; Adult; Antiemetics; California; Diabetes Mellitus, Type 1; Emergency Service, Hospit | 2017 |
Hot Off the Press: SGEM#196: Gastroparesis-I Feel Like Throwing Up.
Topics: Double-Blind Method; Emergency Service, Hospital; Gastroparesis; Haloperidol; Humans; Nausea | 2018 |
Harms From Haloperidol for Symptom Management in Palliative Care-a Post Hoc Pooled Analysis of Three Randomized Controlled Studies and Two Consecutive Cohort Studies.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Delirium; Female; Haloperidol; Humans; Male; Middle A | 2019 |
Haloperidol for treatment of cannabinoid hyperemesis syndrome.
Topics: Abdominal Pain; Adult; Antiemetics; Cannabinoids; Haloperidol; Humans; Male; Marijuana Abuse; Nausea | 2013 |
Prescribing for nausea in palliative care: a cross-sectional national survey of Australian palliative medicine doctors.
Topics: Adult; Antiemetics; Australia; Cross-Sectional Studies; Female; Haloperidol; Humans; Male; Metoclopr | 2014 |
Is haloperidol the wonder drug for cannabinoid hyperemesis syndrome?
Topics: Adult; Antiemetics; Cannabinoids; Haloperidol; Humans; Male; Marijuana Abuse; Nausea; Syndrome; Trea | 2017 |
Haloperidol (Serenase) in the prevention of postoperative nausea and vomiting.
Topics: Anesthesia; Haloperidol; Humans; Hypnotics and Sedatives; Nausea; Postoperative Nausea and Vomiting; | 1962 |
Challenges in palliative care research: one experience.
Topics: Antiemetics; Attitude of Health Personnel; Diphenhydramine; Drug Combinations; Ethics Committees, Re | 2004 |
Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 6-2005. A 58-year-old man with esophageal cancer and nausea, vomiting, and intractable hiccups.
Topics: Adenocarcinoma; Anti-Inflammatory Agents; Antiemetics; Antineoplastic Agents, Hormonal; Barrett Esop | 2005 |
Tolerability of the compound ABHR in hospice patients.
Topics: Aged; Antiemetics; Cohort Studies; Diphenhydramine; Drug Combinations; Female; Haloperidol; Hospice | 2005 |
Prolonged extra-pyramidal side effects after discontinuation of haloperidol as an antiemetic.
Topics: Aged; Antiemetics; Dopamine Antagonists; Female; Haloperidol; Humans; Nausea; Parkinsonian Disorders | 2006 |
Haloperidol as a palliative anti-emetic in a toddler: an evidence base challenge.
Topics: Antiemetics; Evidence-Based Medicine; Fatal Outcome; Haloperidol; Humans; Infant; Male; Nausea; Pall | 2008 |
Lorazepam, diphenhydramine, and haloperidol transdermal gel for rescue from chemotherapy-induced nausea/vomiting: results of two pilot trials.
Topics: Administration, Cutaneous; Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Clini | 2008 |
Lorazepam as an adjunct to antiemetic therapy with haloperidol in patients receiving cytotoxic chemotherapy.
Topics: Anti-Anxiety Agents; Antiemetics; Antineoplastic Agents; Drug Therapy, Combination; Female; Haloperi | 1983 |
Effect of apomorphine on peripheral venous gastrin and insulin levels in conscious dogs.
Topics: Animals; Apomorphine; Dogs; Dose-Response Relationship, Drug; Female; Gastrins; Haloperidol; Insulin | 1981 |
Successful control of intractable nausea and vomiting requiring combined ondansetron and haloperidol in a patient with advanced cancer.
Topics: Analgesics; Bone Neoplasms; Breast Neoplasms; Drug Therapy, Combination; Female; Haloperidol; Humans | 1994 |
The antiemetic efficacy of granisetron plus dexamethasone, haloperidol and loracepam in breast cancer patients treated with high-dose chemotherapy with peripheral blood stem-cell support.
Topics: Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Dexamethasone; | 1998 |
The use of haloperidol to treat nausea.
Topics: Antiemetics; Haloperidol; Humans; Nausea; Neoplasms | 1998 |
Behavioral and neuroendocrine effects of low dose ET-495: antagonism by haloperidol.
Topics: Adult; Dose-Response Relationship, Drug; Growth Hormone; Haloperidol; Humans; Male; Middle Aged; Nau | 1979 |
Compounding nausea aid.
Topics: Benztropine; Chemistry, Pharmaceutical; Dexamethasone; Diphenhydramine; Drug Combinations; Drug Comp | 1991 |
Drug-induced purposeless chewing: animal model of dyskinesia or nausea?
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Antipsychotic Agents; Disease M | 1990 |
Haloperidol and lorazepam for the treatment of nausea and vomiting associated with the treatment of intractable migraine headaches.
Topics: Adult; Dihydroergotamine; Female; Haloperidol; Humans; Lorazepam; Migraine Disorders; Nausea; Vomiti | 1989 |
Continuous subcutaneous infusion: flexible option in symptom control.
Topics: Anxiety; Female; Haloperidol; Humans; Infusion Pumps; Infusions, Parenteral; Metoclopramide; Middle | 1988 |
Haloperidol in the treatment of nausea and vomiting due to cytotoxic drug administration.
Topics: Administration, Oral; Aged; Antineoplastic Agents; Female; Haloperidol; Humans; Male; Middle Aged; N | 1973 |
[The emetic action of theophylline in the dog].
Topics: Animals; Chlorpromazine; Dogs; Dose-Response Relationship, Drug; Emetics; Haloperidol; Myotonia; Nau | 1974 |
The effect of haloperidol with promethazine on postoperative vomiting.
Topics: Anesthesia, General; Atropine; Haloperidol; Humans; Nausea; Promethazine; Vomiting | 1970 |
Occupational health case report--no. 4. Epoxy-type paint.
Topics: Air; Animals; Chromatography, Gas; Dermatitis, Occupational; Environmental Exposure; Epoxy Resins; G | 1974 |